| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.047 | 0.4 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |